CD19 CAR T-cell therapy：Long
Long
由KMCappell著作·2023·被引用434次—CD19-targetedCARTcellsarenowapprovedbytheFDAforthetreatmentofR/RaggressiveBcelllymphomas,mantlecelllymphomasandindolentB ...。其他文章還包含有：「CARTCells」、「CD19CART」、「CD19」、「CD19」、「AggressiveLymphomaafterCD19CART」、「AllogeneicCD19」、「Impactoftumormicroenvironmentonefficacyofanti」
查看更多 離開網站
CAR T Cells
https://www.cancer.gov
CAR T-cell therapies are customized for each individual patient. They are made by collecting T cells from the patient and re-engineering them in the laboratory.
CD19 CAR T
https://www.nejm.org
In this case series, CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious in three different autoimmune diseases.
CD19
https://pubmed.ncbi.nlm.nih.go
Successful use of CD19 CAR-T cells in rheumatic diseases like systemic lupus erythematosus and neuroimmunological diseases like myasthenia ...
CD19
https://ashpublications.org
We review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies.
Aggressive Lymphoma after CD19 CAR T
https://www.nejm.org
CAR T-cell products are approved for the treatment of B-cell acute lymphoblastic leukemia, B-cell lymphomas, and multiple myeloma. Ongoing ...
Allogeneic CD19
https://www.cell.com
Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejection and ...
Impact of tumor microenvironment on efficacy of anti
https://www.nature.com
Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy initially approved for the treatment of relapsed/refractory ...